Clinical trial
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in…
NCT00079742 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00079742 |
|---|---|
| Title | A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis |
| Official title | A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Nutropin AQ [somatropin (DNA origin) injection] |
| Enrollment | 68 |
| Start date | Sep 1, 2003 |
| Completion | May 1, 2007 |
| First posted | Mar 16, 2004 |
| Last update posted | Jun 9, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: